偏最小二乘紫外分光光度法同时测定萘，1－甲基萘和蒽

用偏最小二乘法（ＰＬＳ）进行校正和预测，不经分离同时测定了混合体系中的萘，１－甲基萘和蒽。萘，１－甲基萘和蒽的浓度分别在０～２８ｍｇ／Ｌ，０～４０ｍｇ／Ｌ和０～４０ｍｇ／Ｌ的浓度范围服从比耳定律。对合成样品中这三种组分进行分析，结果令人满意。     

根癌农杆菌介导AtNHX1基因转化小麦

利用根癌农杆菌对 3种基因型小麦进行了转化研究 .发现基因型对转化有明显影响 .将小麦品种烟优 36 1、烟 10 3、核生 3号的胚性愈伤组织用含报告基因NPTⅡ和抗盐基因Na H 反向转运AtNHX1的农杆菌菌株pROK2AT GV310 1感染和共培养后 ,用巴龙霉素 5 0 - 15 0mg L筛选抗性愈伤组织及转化植株 .对抗性植株的总DNA用AtNHX1基因的特异引物进行PCR检测 ,目的基因的PCR阳性频率为 1.3(烟 10 3)和 2 .9% (核生 3号 ) .Southern杂交证实外源基因已经整合到小麦的基因组中     

取值于Banach空间中的（E1）囿变函数

引入取值Ｂａｎａｃｈ空间中的（Ｅ１）囿变函数的概念，并讨论它与强、弱囿变函数之间的关系．     

一种扩展的3-2-1组合夹具定位方法

针对孔系基础板组合夹具定位方案的确定问题，提出了一种扩展的3—2—1的设计方法，介绍了该方法的基本原理，给出了全部设计公式．利用该方法可以自动确定由直线和圆弧组成定位边界的工件的全部可能定位方案．     

(2+1)维色散长波方程的双周期解

借助计算机代数操作系统,引入Jacob ian椭圆函数负幂次展开的方法,求解(2+1)维色散长波方程,得到一系列新的双周期解。     

Understanding the importance of selenium and selenoproteins in muscle function

Selenium is an essential trace element. In cattle, selenium deficiency causes dysfunction of various organs, including skeletal and cardiac muscles. In humans as well, lack of selenium is associated with many disorders, but despite accumulation of clinical reports, muscle diseases are not generally considered on the list. The goal of this review is to establish the connection between clinical observations and the most recent advances obtained in selenium biology. Recent results about a possible role of selenium-containing proteins in muscle formation and repair have been collected. Selenoprotein N is the first selenoprotein linked to genetic disorders consisting of different forms of congenital muscular dystrophies. Understanding the muscle disorders associated with selenium deficiency or selenoprotein N dysfunction is an essential step in defining the causes of the disease and obtaining a better comprehension of the mechanisms involved in muscle formation and maintenance. Received 13 July 2005; received after revision 9 September 2005; accepted 4 October 2005     

多巴胺能神经递质系统在癫痫发生与发展过程中的作用

在癫痫的发生与发展过程中，多巴胺（DA）受体密度及PDA可以发生改变，其变化情况因癫痫类型及不同脑区而异。不同的DA受体在癫痫发生与发展过程中发挥不同的作用，其作用也与癫痫类型等因素有关。     

Cancer and blood coagulation

In human patients, blood coagulation disorders often associate with cancer, even in its early stages. Recently, in vitro and in vivo experimental models have shown that oncogene expression, or inactivation of tumour suppressor genes, upregulate genes that control blood coagulation. These studies suggest that activation of blood clotting, leading to peritumoral fibrin deposition, is instrumental in cancer development. Fibrin can indeed build up a provisional matrix, supporting the invasive growth of neoplastic tissues and blood vessels. Interference with blood coagulation can thus be considered as part of a multifaceted therapeutic approach to cancer. Received 30 November 2005; received after revision 7 February 2005; accepted 8 February 2006     

1-(6-硝基-2-苯并噻唑)-3-(4-硝基苯)-三氮烯与镍显色反应的研究及应用

在TritonX-100表面活性剂存在下,研究了1-(6-硝基-2-苯并噻唑)-3-(4-硝基苯)-三氮烯(NBTNPT)与镍的显色反应.在pH为10.0～11.5的Na2B4O7-NaOH缓冲溶液中,该试剂与镍生成2∶1配合物.以500nm为参比波长,440nm为测定波长的双峰双波长进行测定,表观摩尔吸光系数为1.84×105L·mol-1·cm-1.Ni2+的浓度在0～280μg/L内符合比耳定律.用拟定方法测定钢铁中的微量镍,结果满意.     

Podocalyxin enhances the adherence of cells to platelets

Podocalyxin (PODXL) is a mucin protein of the CD34 family expressed in kidney glomerular podocytes, vascular endothelium, progenitor bone marrow and tumor cells. It is assumed that PODXL plays an anti-adherent role in kidney podocytes. CHO cells stably expressing human PODXL (CHO-PODXL) or human tumor cells (Tera-1) inherently expressing PODXL showed increased adherence to platelets. The adherence of cells was inhibited (70%) by blockers of platelet P-selectin, prevented by the soluble ectodomain of human PODXL (PODXL-Δ) or by the arginine-glycine-aspartate (RGDS) peptide and partially impeded by inhibition of integrin αVβ3/αVβ5, suggesting a coordinated action of P-selectin and integrins. Colocalization of platelet P-selectin and PODXL expressed on CHO cells was demonstrated by confocal immunofluorescence. No adherence to platelets was observed when PODXL was expressed in glycomutant CHO cells deficient in sialic acid. Received 14 August 2007; received after revision 12 September 2007; accepted 13 September 2007